CapsoVision (CV) vs Solana (HSDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed Solana (HSDT) over the past year, gaining 16.8% versus a loss of 53.7%. CapsoVision is the larger company by market cap ($327.6 million vs $93.7 million), about 3.5 times the size, while Solana is growing revenue faster (+1057.1% vs +15.3%). CapsoVision converts more of its revenue into profit, with a net margin of -186.8% versus -679.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | HSDT |
|---|---|---|
| Share price | $6.11 | $1.49 |
| Market cap | $327.56M | $93.70M |
| 1-day change | -3.17% | -10.24% |
| YTD return | -42.84% | -48.44% |
| 1-year return | +16.83% | -53.73% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 0.02 |
| EPS (TTM) | $-0.42 | $87.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $6.02M |
| Revenue growth (YoY) | +15.29% | +1057.12% |
| Net income (latest FY) | $-25.32M | $-40.89M |
| Gross margin | 52.92% | 91.69% |
| Operating margin | -188.25% | -4052.52% |
| Net margin | -186.77% | -679.57% |
| 52-week high | $15.37 | $4.36 |
| 52-week low | $4.50 | $1.19 |
| Distance from 52-week high | -60.25% | -65.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.48% | +134.90% |
| Average volume | 173.59K | 579.67K |
| Shares outstanding | 53.61M | 62.89M |
| Employees | 99 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CapsoVision is about 3.5 times larger than Solana by market value ($327.56M vs $93.70M).
- CV has outperformed HSDT by 70.6 percentage points over the past year.
- CapsoVision is more profitable, keeping -186.8 cents of every revenue dollar as net income versus -679.6 cents for Solana.
- Solana grew revenue faster in its latest fiscal year (+1057.12% vs +15.29%).
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About Solana
HSDT stock →Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 21 employees
CV vs HSDT FAQ
Which is bigger, CapsoVision or Solana?
CapsoVision (CV) is larger, with a market capitalization of $327.56M compared with $93.70M for Solana (HSDT).
Which stock has performed better over the past year, CV or HSDT?
CV returned +16.83% over the past 12 months, compared with -53.73% for HSDT (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Solana in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.